Ptc Therapeutics (PTCT) Total Non-Current Liabilities (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Total Non-Current Liabilities of $3.4 billion for Q2 2026, up 20.07% year-over-year from $2.8 billion in Q2 2025, and up 12.04% quarter-over-quarter from $3.0 billion in Q1 2026.
Ptc Therapeutics (PTCT) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $3.4 billion for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 20.07% year-over-year to $3.4 billion; the TTM figure through Jun 2026 stood at $3.4 billion (up 20.07% YoY), while the FY2025 annual figure was $3.1 billion, up 11.1% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $3.4 billion, up from $3.0 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $3.4 billion in Q2 2026, with the low at $1.6 billion in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $2.7 billion (2023), against an average of $2.5 billion.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities soared 52.95% in 2024, then retreated 2.7% in 2025.
- Ptc Therapeutics' Total Non-Current Liabilities stood at $1.9 billion in 2022, then jumped by 41.79% to $2.7 billion in 2023, then advanced by 3.87% to $2.8 billion in 2024, then advanced by 11.1% to $3.1 billion in 2025, then climbed by 10.06% to $3.4 billion in 2026.
- Business Quant data shows PTCT's Total Non-Current Liabilities at $3.4 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 3.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.40 Bn |
| Mar 31, 2026 | 3.04 Bn |
| Dec 31, 2025 | 3.09 Bn |
| Sep 30, 2025 | 2.80 Bn |
| Jun 30, 2025 | 2.83 Bn |
| Mar 31, 2025 | 2.84 Bn |
| Dec 31, 2024 | 2.80 Bn |
| Sep 30, 2024 | 2.90 Bn |
| Jun 30, 2024 | 2.90 Bn |
| Mar 31, 2024 | 2.65 Bn |
| Dec 31, 2023 | 2.71 Bn |
| Sep 30, 2023 | 1.93 Bn |
| Jun 30, 2023 | 1.92 Bn |
| Mar 31, 2023 | 2.07 Bn |
| Dec 31, 2022 | 1.89 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 1.82 Bn |
| Mar 31, 2022 | 1.66 Bn |
| Dec 31, 2021 | 1.70 Bn |
| Sep 30, 2021 | 1.65 Bn |